Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
10 papers
Researchers are testing several new and old approaches to treat addiction. The most attention is on psychedelic-assisted psychotherapy — that is, giving a drug like psilocybin, MDMA, or ibogaine together with careful therapy — and on new drug compounds tested in animals. Some early clinical trials and many reviews call these approaches “promising,” but most evidence is still limited, mixed, or from small studies. At the same time, for some substances like methamphetamine there are no approved medicines that clearly reduce use. Animal studies and new chemical versions of old drugs show strong early results, but human safety and larger trials are still needed. Researchers also stress that the drug effect and the therapy around it (preparation, setting, and follow-up) both matter for how well treatment works.
This review looked at many studies about classic psychedelics (like psilocybin and LSD), MDMA, ketamine, and plant medicines (like ayahuasca). The authors explain how these drugs can change the brain’s wiring, calm inflammatory processes, and shift key brain chemicals. Those actions may help explain why small clinical trials and animal…
This review explains the fast-growing problem of so-called "legal highs", which are better called novel psychoactive substances or NPS. Unknown labs keep making slightly different chemicals to avoid bans, and this led to about 80 new substances being spotted in one year. The paper groups these drugs into five main…
Researchers looked at sixty studies to see how biology, social life, and psychology mix together to affect substance use problems and mental health. They found that brain systems, genes, childhood experiences, parenting, personality, and existing mood or anxiety problems all interact. This makes addiction and related psychiatric symptoms complicated, especially…
This paper reviewed studies since 2016 to identify cannabis-related factors linked with higher risk of psychosis. It found that personal and genetic vulnerability, earlier age of first use, more frequent use, higher-THC products, how cannabis is taken, and using other drugs all raise the odds of cannabis-related psychosis. Evidence that…
Researchers ran three focus groups with 14 people who have depression but had not tried ketamine. Participants saw ketamine as promising but were worried about its reputation as a party drug, possible long-term harms, and how it would be monitored. They wanted clear public information, better evidence about long-term safety,…
This paper reviews what medicines have been tested to treat methamphetamine use disorder in animals and people. The authors say there are still no approved drugs that reliably cut cravings or help people stop using meth. Some medicines helped in animal tests but did not lower meth use in people,…
Researchers made new versions of the psychedelic drug ibogaine, called oxa-iboga compounds, by changing part of the chemical structure. In lab tests on human heart cells these new compounds did not show the heart-rhythm risk that ibogaine can cause. In tests with male rats, a single dose or a short…
This systematic review looked at 16 studies of ketamine used to treat adults with depression, covering 2,174 patients. The authors found few clear cases of tolerance or dependence (four patients) and conclude that, overall, ketamine appears relatively safe for depression when given under medical supervision, with careful monitoring and dosing.…
This paper is a first look at whether the fast-acting psychedelic 5‑MeO‑DMT might help people with alcohol use disorder. The authors reviewed existing studies in humans and animals and found early signs that 5‑MeO‑DMT can cause intense mystical feelings and a loss of self-boundaries, and that it changes brain rhythms…
This paper reviews research on ayahuasca and its main ingredient, DMT, and how they might help with mental health. Ayahuasca is a plant brew that makes DMT work when you drink it because it also contains chemicals that stop the body from breaking DMT down. Lab studies and a small…
